Flotufolastat F 18 clinical trials
Also written Posluma and flotufolastat F18.
How each study uses flotufolastat F 18 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the flotufolastat F 18 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2025 (8)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 8 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 10
Blue Earth Diagnostics (4) · Sinotau Pharmaceutical Group (2) · NYU Langone Health (1) · M.D. Anderson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Emory University (1) · Northwestern University (1) · University of Florida (1)
Often tested with
Tested in the same studies.
Piflufolastat (1) · Lutetium-177 (1) · Gallium 68 PSMA-11 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test flotufolastat F 18.
- Feb 2027An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN TrialEarly Phase 1 · Northwestern University
- May 2027Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active SurveillancePhase 2 · Icahn School of Medicine at Mount Sinai
Studies
Open first, then newest update. How each study uses flotufolastat F 18 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.RecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07185165Written as Fluorine F 18 Flotufolastat
- An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion TechniqueRecruitingPhase 2Emory UniversityNCT06865768Written as Flotufolastat F-18 Gallium
- An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN TrialRecruitingEarly Phase 1Northwestern UniversityNCT06813898Written as Flotufolastat F-18 Gallium
- POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 LesionsRecruitingPhase 2University of FloridaNCT07220720Written as Flotufolastat F 18
- Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland TreatmentRecruitingNot applicableHackensack Meridian HealthNCT07011342Written as 18F-rhPSMA-7.3
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active SurveillanceRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT07285057Written as Flotufolastat F18
- Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical ManagementRecruitingPhase 3MidLantic UrologyNCT05799248Written as rhPSMA-7.3 (18F)
- A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese AdultsCompletedPhase 1Sinotau Pharmaceutical GroupNCT07149831Written as Flotufolastat F-18 Injection
- Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate CancerCompletedNot applicableSinotau Pharmaceutical GroupNCT07115277Written as Flotufolastat F-18 Injection
- Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical ProstatectomyCompletedPhase 4Blue Earth DiagnosticsNCT06604442Written as flotufolastat (18F)
- Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical ProstatectomyActive, not recruitingPhase 3NYU Langone HealthNCT05678322Written as 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
- Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate CancerCompletedPhase 1Blue Earth DiagnosticsNCT03995888Written as rhPSMA-7.3 (18F) Injection
- Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPCWithdrawnPhase 1/2Novartis PharmaceuticalsNCT06881823Written as Flotufolastat F 18
- Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer RecurrenceCompletedPhase 3Blue Earth DiagnosticsNCT04186845Written as rhPSMA-7.3 (18F) Injection
- Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.CompletedPhase 3Blue Earth DiagnosticsNCT04186819Written as rhPSMA-7.3 (18F) Injection
- An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT04978675Written as Fluorine F 18 rhPSMA-7.3
- 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot StudyWithdrawnEarly Phase 1University of Alabama at BirminghamNCT05707182Written as 18F-rhPSMA-7.3
Codes
What other systems call flotufolastat F 18 · ClinicalTrials.gg INT002169
- MeSH (NLM) C000731939flotufolastat F 18One source NLM
- UNII (FDA) 811W19E3OLFLOTUFOLASTAT F-18Confirmed FDA, NLM, Wikidata
- Wikidata Q120497866flotufolastat F-18Confirmed FDA, NLM, Wikidata
- Wikidata Q120693652flotufolastatConfirmed FDA, NLM, Wikidata
- DrugBank DB17851One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731939 | flotufolastat F 18 | One source NLM |
| UNII (FDA) | 811W19E3OL | FLOTUFOLASTAT F-18 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q120497866 | flotufolastat F-18 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q120693652 | flotufolastat | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB17851 | — | One source Wikidata |
Also registered as flotufolastat f-18 gallium (UNII XD423NK2WO).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.